论文部分内容阅读
应用鼠伤寒沙门氏菌/微粒体试验研究了14种化合物的抗突变性。14种化合物是:(1)半胱氨酸、(2)桂皮酸、(3)芦丁、(4)鞣酸、(5)二氧化锗、(6)5氟尿嘧啶、(7)叶绿素铜钠、(8)β谷固醇、(9)维生素C、(10)香豆素、(11)维生素E、(12)L谷胱甘肽(氧化型)、(13)L谷胱甘肽(还原型)、(14)有机锗(GA)。实验按抑制突变、抗突变和去突变3种作用模式研究了化合物的抗突变效应。结果表明,除二氧化锗外,所有测试化合物均能抑制亚硝基胍(MNNG)和苯(并)芘[B(a)P]的致突变性。化合物1、2、3、4、6、8、10和12的抑制率在90％以上。14种化合物对MNNG的致突性有抗突变效应,12种化合物对B(a)P有抗突变效应,唯二氧化锗和GA对B(a)P无抗突变作用。在B(a)P作用于细胞前,14种化合物对B(a)P有直接的去突变作用。根据作用模式和作用潜力,1、2、3、4和10在14种化合物中是较好的抗突变剂,并呈现剂量-反应关系。每种化合物都有其有效剂量,化合物 2、6、7、8、10、11为500μg,化合物1、3、4、12、13、14为1000μg,化合物5、9为1250μg。研究表明,有必要选择有效的抗突变剂制成复方,并研究其协同作用。
Anti-mutagenicity of 14 compounds was investigated using Salmonella typhimurium / microsome assays. The 14 compounds are: (1) cysteine, (2) cinnamic acid, (3) rutin, (4) tannic acid, (5) germanium dioxide, (6) 5 fluorouracil, (8) betaglutaryl alcohol, (9) vitamin C, (10) coumarin, (11) vitamin E, (12) L glutathione Reduced), (14) Organic Germanium (GA). In the experiment, the antimutagenic effects of the compounds were studied by three modes of action of inhibiting mutation, anti-mutation and de-mutation. The results showed that all of the tested compounds inhibited the mutagenicity of nitrosoguanidine (MNNG) and benzo (and) pyrene [B (a) P] except for germanium dioxide. The inhibitory rates of compounds 1, 2, 3, 4, 6, 8, 10 and 12 were over 90%. Fourteen compounds have anti-mutagenic effects on MNNG, 12 compounds have anti-mutagenic effects on B (a) P, while only germanium dioxide and GA have no anti-mutagenic effect on B (a) P. Fourteen compounds have a direct de-mutagenesis of B (a) P before B (a) P acts on the cells. According to the mode of action and potential of action, 1, 2, 3, 4 and 10 are the best anti-mutants among the 14 compounds, showing a dose-response relationship. Each compound has its effective dose, compound 2, 6, 7, 8, 10, 11 is 500 μg, compound 1, 3, 4, 12, 13, 14 is 1000 μg, compound 5, 9 is 1250 μg. Studies have shown that it is necessary to select effective anti-mutagen to make the compound and to study its synergistic effect.